当前位置: X-MOL 学术J. Biotechnol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Expression of immunogenic poliovirus Sabin type 1 VP proteins in transgenic tobacco.
Journal of Biotechnology ( IF 4.1 ) Pub Date : 2020-07-10 , DOI: 10.1016/j.jbiotec.2020.07.007
Omayra C Bolaños-Martínez 1 , Dania O Govea-Alonso 2 , Jacquelynne Cervantes-Torres 3 , Marisela Hernández 3 , Gladis Fragoso 3 , Edda Sciutto-Conde 3 , Sergio Rosales-Mendoza 2
Affiliation  

One of the milestones of vaccinology is the depletion of the global impact of Poliomyelitis. The current vaccines to deal with Polio comprise the Sabin and Salk formulations. The main limitation of the former is the use of attenuated viruses that can revert into pathogenic forms, whereas the latter is more expensive and induces no protection in the intestinal tract; the site of virus replication. Genetically engineered plants cope with such limitations. In addition, they offer a low-cost alternative for production, storage and delivery of vaccines. This technology has been narrowly applied in the development of Polio vaccines.

Herein, we explored the ability of tobacco cells to express the immunogenic VP1, VP2, VP3, and VP4 Polio antigens, which are relevant for vaccine development. Evidence on the expression of the plant-made Polio VPs is presented and an immunogenicity assessment proved their capacity to induce local and systemic humoral responses when administered by subcutaneous and oral routes. The plant-made VPs will be useful in the development of low-cost vaccine formulations able to induce effective mucosal immunity without the risks associated to the use of attenuated viruses; therefore there is a potential for this technology to contribute toward Polio eradication.



中文翻译:

免疫原性脊髓灰质炎沙宾1型VP蛋白在转基因烟草中的表达。

疫苗学的一个里程碑是减少脊髓灰质炎的全球影响。当前用于治疗脊髓灰质炎的疫苗包括萨宾和索尔克制剂。前者的主要局限性是使用了可还原为病原体形式的减毒病毒,而后者则更昂贵,并且在肠道中没有任何保护作用。病毒复制的站点。基因工程植物可以应对这种局限性。此外,它们为疫苗的生产,储存和交付提供了一种低成本的替代品。该技术已狭窄地应用于脊髓灰质炎疫苗的开发中。

在本文中,我们探索了烟草细胞表达与疫苗开发相关的免疫原性VP1,VP2,VP3和VP4脊髓灰质炎抗原的能力。提出了有关人造脊髓灰质炎病毒表达的证据,免疫原性评估证明了当通过皮下和口服途径给药时,它们能够诱导局部和全身性体液反应。植物制成的VPs将用于开发低成本的疫苗制剂,该制剂能够诱导有效的粘膜免疫,而不会产生使用减毒病毒的风险。因此,这项技术有可能有助于根除脊髓灰质炎。

更新日期:2020-07-16
down
wechat
bug